Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil

被引:152
作者
Tracy, TS
Korzekwa, KR
Gonzalez, FJ
Wainer, IW
机构
[1] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
[2] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA USA
[3] NCI, NIH, Bethesda, MD 20892 USA
[4] McGill Univ, Dept Oncol, Pharmacokinet Div, Montreal, PQ, Canada
关键词
cytochrome P450; enantiomer; metabolism; norverapamil; verapamil;
D O I
10.1046/j.1365-2125.1999.00923.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The present study was conducted to evaluate metabolism of the enantiomers of verapamil and norverapamil using a broad range of cytochrome P450 isoforms and measure the kinetic parameters of these processes. Methods Cytochrome P450 cDNA-expressed cells and microsomes from a P450-expressed lymphoblastoid cell line were incubated with 40 mu M concentrations of R- or S-verapamil and R- or S-norverapamil and metabolite formation measured by h.p.l.c. as an initial screening. Those isoforms exhibiting substantial activity were then studied over a range of substrate concentrations (2.5-450 mu M) to estimate the kinetic parameters for metabolite formation. Results P450s 3A4, 3A5, 2C8 and to a minor extent 2E1 were involved in the metabolism of the enantiomers of verapamil. Estimated K-m values for the production of D-617 and norverapamil by P450s 3A4 and 3A5 were similar (range = 60-127 mu M) regardless of the enantiomer of verapamil studied while the V-max estimates were also similar (range = 4-8 pmol min(-1) pmol(-1) P450). Only nominal production of D-620 by these isoforms was noted. Interestingly, P450 2C8 readily metabolized both S- and R-verapamil to D-617, norverapamil and PR-22 with only slightly higher K-m values than noted for P450s 3A4 and 3A5. However, the V-max estimates for P450 2C8 metabolism of S- and R-verapamil were in general greater (range = 8-15 pmol min(-1) pmol(-1) P450) than those noted for P450 s 3A4 and 3A5 with preference noted for metabolism of the S-enantiomer. Similarly, P450 s 3A4, 3A5 and 2C8 also mediated the metabolism of the enantiomers of norverapamil with minor contributions by P450 s 2D6 and 2E1. P450s 3A4 and 3A5 readily formed the D-620 metabolite with generally a lower K-m and higher V-max for S-norverapamil than for the R-enantiomer. In contrast, P450 2C8 produced both the D-620 and PR-22 metabolites from the enantiomers of norverapamil, again with stereoselective preference seen for the S-enantiomer. Conclusions These results confirm that P450s 3A4, 3A5 and 2C8 play a major role in verapamil metabolism and demonstrate that norverapamil can also be further metabolized by the P450s.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 19 条
[1]  
Busse D, 1995, N-S ARCH PHARMACOL, V353, P116
[2]  
EICHELBAUM M, 1979, DRUG METAB DISPOS, V7, P145
[3]   EFFECTS OF VERAPAMIL ON P-R-INTERVALS IN RELATION TO VERAPAMIL PLASMA-LEVELS FOLLOWING SINGLE IV AND ORAL-ADMINISTRATION AND DURING CHRONIC TREATMENT [J].
EICHELBAUM, M ;
BIRKEL, P ;
GRUBE, E ;
GUTGEMANN, U ;
SOMOGYI, A .
KLINISCHE WOCHENSCHRIFT, 1980, 58 (18) :919-925
[4]  
Fromm MF, 1996, HEPATOLOGY, V24, P796
[5]  
FUHR U, 1992, EUR J CLIN PHARMACOL, V42, P463
[6]  
GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P85
[7]   BIOAVAILABILITY OF CYCLOSPORINE WITH CONCOMITANT RIFAMPIN ADMINISTRATION IS MARKEDLY LESS THAN PREDICTED BY HEPATIC ENZYME-INDUCTION [J].
HEBERT, MF ;
ROBERTS, JP ;
PRUEKSARITANONT, T ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :453-457
[8]   Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations [J].
Kantola, T ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (02) :177-182
[9]   THE SPECIFICITY OF INHIBITION OF DEBRISOQUINE 4-HYDROXYLASE ACTIVITY BY QUINIDINE AND QUININE IN THE RAT IS THE INVERSE OF THAT IN MAN [J].
KOBAYASHI, S ;
MURRAY, S ;
WATSON, D ;
SESARDIC, D ;
DAVIES, DS ;
BOOBIS, AR .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (17) :2795-2799
[10]   1ST-PASS METABOLISM OF CYCLOSPORINE BY THE GUT [J].
KOLARS, JC ;
AWNI, WM ;
MERION, RM ;
WATKINS, PB .
LANCET, 1991, 338 (8781) :1488-1490